Clinical Trial: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758075) titled 'A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis' on July 27.

Brief Summary: This study is a randomized, double-blind, multicenter, dose-parallel-controlled phase II clinical trial.

The study consists of three stages: a 4-week screening period, a 52-week treatment period, and a 12-week follow-up period. For the qualified participants screened, using body weight (>=90 kg or < 90 kg) and whether participants had a poor response to IL-12/23p40 inhibitors in the past (yes vs no) as stratification factors, they were randomly assigned to two groups in a 1:1 ratio: Group...